Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 58,354,752
  • Shares Outstanding, K 132,114
  • Annual Sales, $ 2,248 M
  • Annual Income, $ -278,160 K
  • EBIT $ 265 M
  • EBITDA $ 321 M
  • 60-Month Beta 0.30
  • Price/Sales 26.01
  • Price/Cash Flow N/A
  • Price/Book 250.06

Options Overview Details

View History
  • Implied Volatility 41.63% ( +1.60%)
  • Historical Volatility 34.96%
  • IV Percentile 62%
  • IV Rank 31.38%
  • IV High 68.01% on 04/08/25
  • IV Low 29.56% on 08/13/25
  • Put/Call Vol Ratio 1.56
  • Today's Volume 382
  • Volume Avg (30-Day) 1,141
  • Put/Call OI Ratio 0.68
  • Today's Open Interest 35,851
  • Open Int (30-Day) 30,778

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 1.01
  • Number of Estimates 12
  • High Estimate 2.53
  • Low Estimate -0.12
  • Prior Year -0.65
  • Growth Rate Est. (year over year) +255.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
417.00 +8.38%
on 11/05/25
495.55 -8.80%
on 10/20/25
-8.51 (-1.85%)
since 10/10/25
3-Month
417.00 +8.38%
on 11/05/25
495.55 -8.80%
on 10/20/25
+16.95 (+3.90%)
since 08/11/25
52-Week
205.87 +119.53%
on 04/09/25
495.55 -8.80%
on 10/20/25
+172.13 (+61.51%)
since 11/11/24

Most Recent Stories

More News
New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM

− Analyses Presented at the American Heart Association Scientific Sessions 2025 Underscore Vutrisiran’s Differentiated Profile – − Cardiovascular Magnetic Resonance...

ALNY : 451.95 (+2.32%)
Alnylam to Webcast Presentations at Upcoming November Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences: ...

ALNY : 451.95 (+2.32%)
Alnylam: Q3 Earnings Snapshot

Alnylam: Q3 Earnings Snapshot

ALNY : 451.95 (+2.32%)
Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress

− Generated Q3 2025 Total Net Product Revenues of $851 Million (103% Growth Compared with Q3 2024), Driven Primarily by Total TTR Revenues of $724 Million (135% Growth Compared with Q3 2024) – ...

ALNY : 451.95 (+2.32%)
Alnylam Pharma (ALNY) Gets a Hold from Leerink Partners

Leerink Partners analyst Mani Foroohar maintained a Hold rating on Alnylam Pharma yesterday and set a price target of $370.00. The company’s shares closed yesterday at $470.27.Elevate Your Investing...

ALNY : 451.95 (+2.32%)
Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2025 on Thursday,...

ALNY : 451.95 (+2.32%)
H.C. Wainwright Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Alnylam Pharma, with a price target of $570.00. The company’s shares closed yesterday at $456.95.Elevate Your...

ALNY : 451.95 (+2.32%)
RBC Capital Sticks to Their Buy Rating for Alnylam Pharma (ALNY)

In a report released on October 8, Luca Issi from RBC Capital maintained a Buy rating on Alnylam Pharma. The company’s shares closed yesterday at $456.95.Elevate Your Investing Strategy: Take advantage...

ALNY : 451.95 (+2.32%)
Alnylam and Regeneron Join Forces in Promising Alzheimer’s Study

Alnylam Pharmaceuticals ((ALNY)), Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off!...

ALNY : 451.95 (+2.32%)
REGN : 674.55 (+3.03%)
Alnylam Pharma (ALNY) Gets a Hold from Morgan Stanley

In a report released today, Michael Ulz from Morgan Stanley maintained a Hold rating on Alnylam Pharma, with a price target of $475.00. The company’s shares closed last Friday at $456.35.Elevate Your...

ALNY : 451.95 (+2.32%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Alnylam Pharmaceuticals Inc. is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference. The company's pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic areas - genetic medicines, cardio-metabolic...

See More

Key Turning Points

3rd Resistance Point 471.69
2nd Resistance Point 463.44
1st Resistance Point 457.70
Last Price 451.95
1st Support Level 443.71
2nd Support Level 435.46
3rd Support Level 429.72

See More

52-Week High 495.55
Last Price 451.95
Fibonacci 61.8% 384.89
Fibonacci 50% 350.71
Fibonacci 38.2% 316.53
52-Week Low 205.87

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar